AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15695501
Drug: Bolus 5-FU/LV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus 5-FU/LV (5-FU 425 mg/m2 i.v. and LV 20 mg/m2 i.v. bolus days 1-5 every 28 days for 6 months)
Trial: 15695501
Drug: PVI 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PVI 5-FU (300 mg/m2/day for 12 weeks)
Trial: 2853055
Drug: ICI 118551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118551 25 mg
Trial: 2853055
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg + ICI 118551 25 mg
Trial: 2853055
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg + ICI 118551 25 mg
Trial: 21052022
Drug: β-blocker or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blocker or diuretic monotherapy
Trial: 21052022
Drug: β-blocker and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blocker and/or diuretic treatment
Trial: 21052022
Drug: diltiazem treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem treatment
Trial: 18569138
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg nightly for 14 nights (Control group)
Trial: 18569138
Drug: Symptom-oriented hypnotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-oriented hypnotherapy, twice-a-week 1.5-hour sessions for 2 weeks (Intervention group)
Trial: 14575233
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ofloxacin and tinidazole
Trial: 8806332
Drug: Recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) with adjunctive antithrombotic therapy (hirudin or heparin)
Trial: 6824189
Drug: Pentoxifylline (Trental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (Trental 400 tablets with 400 mg active ingredient)
Trial: 29724511
Drug: MenACWY-TT (booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT (booster dose)
Trial: 22802220
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (8‐ to 12‐week treadmill exercise program, target lactate 2.0±0.5 mmol/L)
Trial: 10430379
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose octreotide (0.5 microg/kg/hr by continued i.v. infusion)
Trial: 10430379
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose octreotide
Trial: 2190515
Drug: Corticosteroids (prednisone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (prednisone, 60 mg/d for 7 days, followed by a progressive tapering over 14 days)
Trial: 26208959
Drug: Bapineuzumab 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 0.5 mg/kg
Trial: 20505438
Drug: Bapineuzumab 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 1.5 mg/kg
Trial: 20505438
Drug: Bapineuzumab 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 5.0 mg/kg
Trial: 30412493
Drug: Bapineuzumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab (all doses)
Trial: 11832135
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin 1 microg x kg(‐1) x min(‐1) perioperatively
Trial: 6733563
Drug: Intravenous misonidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous misonidazole with 10 fractions of 400 rad each
Trial: 26691888
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg thrice-daily for 6 months
Trial: 23276524
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (pharmacological + psychoeducational and cognitive-behavioral therapy)
Trial: 15625142
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg ethinyl/estradiol plus 3 mg drospirenone (group A)
Trial: 12413987
Drug: OGTT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGTT with IV injection of naloxone
Trial: 12413987
Drug: HRT (estro‐progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (estro‐progestin combined therapy)
Trial: 10207542
Drug: HIV-1 p24
RxNorm normalized name: HIV-1 p24 Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 p24 antibody
Trial: 10207542
Drug: HIV-1 p24
RxNorm normalized name: HIV-1 p24 Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 p24 antibody < 5 RTU
Trial: 30378288
Drug: Levosimendan infusions
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan infusions
Trial: 28388244
Drug: New drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drugs in patients with relapsed and/or refractory MM
Trial: 28388244
Drug: Novel anti-MM
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel anti-MM drugs
Trial: 28388244
Drug: New therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New therapies in the management of patients with newly diagnosed MM
Trial: 22249393
Drug: Coffee enema
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee enema (3 times weekly for 6 visits)
Trial: 22249393
Drug: Oral coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral coffee consumption (2 times daily for 11 days)
Trial: 20305034
Drug: Gonadotropin-releasing hormone-analogues
RxNorm normalized name: Gonadotropin releasing hormone analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone-analogues (GnRH-a)
Trial: 15663548
Drug: 22-oxacalcitriol (OCT)
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 22-oxacalcitriol (OCT) 5 microg, 10 microg, or 15 microg administered at the end of every HD for 12 weeks
Trial: 15663548
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose OCT groups
Trial: 7895356
Drug: Acetylcholine (0.15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 micrograms/100 mL per minute)
Trial: 7895356
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (1, 2, and 4 micrograms/100 mL per minute)
Trial: 6947984
Drug: 600 ml
RxNorm normalized name: urinary bag 600 mL-10" MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 ml placebo (Group C)
Trial: 6947984
Drug: 600 ml
RxNorm normalized name: urinary bag 600 mL-10" MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 ml 0.05% chlorhexidine digluconate (Group E)
Trial: 6947984
Drug: 600 ml
RxNorm normalized name: urinary bag 600 mL-10" MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 ml 0.05% chlorhexidine digluconate (Group D)
Trial: 26449252
Drug: anti-H.pylori treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-H.pylori treatment
Trial: 26449252
Drug: anti-H.pylori followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-H.pylori followed by celecoxib treatment
Trial: 15162156
Drug: Pain management
RxNorm normalized name: Olu Pain Management 4%-1% Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain management (analgesic treatment)
Trial: 9440175
Drug: Sequential bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential bilateral LASIK
Trial: 7944444
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (EPIR) < 30 mg/m2
Trial: 7944444
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (EPIR) >= 30 - < 40 mg/m2
Trial: 7944444
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (EPIR) >= 40 - < 50 mg/m2
Trial: 7944444
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (EPIR) >= 50 - < 60 mg/m2
Trial: 7944444
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (EPIR) >= 60 mg/m2
Trial: 29307112
Drug: 200 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg/day of chromium for 8 weeks
Trial: 27494260
Drug: H2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 vaccine
Trial: 27494260
Drug: hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hepatitis B vaccine
Trial: 18387162
Drug: Intravenous alfacalcidol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfacalcidol once weekly (Group 1)
Trial: 18387162
Drug: Intravenous alfacalcidol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfacalcidol twice weekly (Group 2)
Trial: 16627223
Drug: ertapenem 1
RxNorm normalized name: ertapenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ertapenem 1 g daily
Trial: 16627223
Drug: piperacillin/tazobactam 13.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperacillin/tazobactam 13.5 g daily in 3-4 divided doses
Trial: 12682719
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 150 mg/kg bolus followed by 12 mg/kg/h continuous infusion
Trial: 1433889
Drug: Imipenem (IPM)
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem (IPM) (1.0‐1.5 g/day)
Trial: 1433889
Drug: Aztreonam (AZT)
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aztreonam (AZT) (4 g/day) + Lincomycin (LCM) (1,200‐2,400 mg/day)
Trial: 4008815
Drug: lodoxamide tromethamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lodoxamide tromethamine, 0.25 mg four times daily
Trial: 27112322
Drug: Experimental agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental agents in the MIDAS trial
Trial: 27112322
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm with standard therapy
Trial: 20875371
Drug: linagliptin 10
RxNorm normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 10 mg/day
Trial: 20875371
Drug: linagliptin and
RxNorm normalized name: linagliptin and empagliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin and pioglitazone co-administration
Trial: 14967867
Drug: Eucaloric diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucaloric diet providing 8 g of CHO/kg of body weight
Trial: 14967867
Drug: Eucaloric diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucaloric diet providing 5 g of CHO/kg of body weight
Trial: 14967867
Drug: Eucaloric diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucaloric diet providing 3 g of CHO/kg of body weight
Trial: 10930106
Drug: Vinorelbine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 30 mg/m2 i.v. weekly
Trial: 10930106
Drug: Leucovorin 100
RxNorm normalized name: leucovorin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin 100 mg/m2 i.v. followed by 5-fluorouracil 370 mg/m2 i.v. days 1-5, q 28 days
Trial: 10930106
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m2 i.v. only day 1 + leucovorin 100 mg/m2 i.v. followed by 5-fluorouracil 370 mg/m2 i.v. days 1-3, q 28 days
Trial: 1464655
Drug: Testosterone Only
RxNorm normalized name: Testosterone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Only group (200 mg testosterone enanthate weekly for 8 weeks)
Trial: 1464655
Drug: Placebo/Testosterone group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/Testosterone group (placebo for first 4 weeks, then 200 mg testosterone enanthate weekly for next 4 weeks)
Trial: 1464655
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (placebo injections for first 4 weeks)
Trial: 28204882
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 50 µg
Trial: 28204882
Drug: Both routes
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both routes (sublingual and vaginal)
Trial: 24528531
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg bupivacaine plus 8 mg dexamethasone (active group)
Trial: 24528531
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL saline (placebo group)
Trial: 22743295
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/d plus erlotinib 150 mg/d
Trial: 22743295
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus erlotinib 150 mg/d
Trial: 18330698
Drug: Triptorelin (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (3.75 mg on days 1 and 29) + Exemestane (25 mg once daily for 8 weeks)
Trial: 18330698
Drug: Triptorelin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin alone (3.75 mg on days 1 and 29)
Trial: 11574775
Drug: No initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No initial chemotherapy exposure
Trial: 11574775
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy response
Trial: 9448611
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition through a central venous catheter (n = 20)
Trial: 8073865
Drug: Nasal challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal challenge with bradykinin (1 mg in 10% ethanol in 0.9% saline)
Trial: 8073865
Drug: Oropharyngeal challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal challenge with bradykinin (1 mg in 10% ethanol in 0.9% saline)
Trial: 28744992
Drug: Carnosine 1
RxNorm normalized name: carnosine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnosine 1 g/day for 12 weeks
Trial: 12492740
Drug: rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole (20 mg b.d.), amoxicillin (750 mg b.d.), metronidazole (250 mg b.d.) for 1 week
Trial: 12492740
Drug: rabeprazole-amoxicillin-metronidazole
RxNorm normalized name: rabeprazole, amoxicillin and metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole-amoxicillin-metronidazole
Trial: 10594201
Drug: Prophylactic systemic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic systemic antibiotics plus syringe pressure irrigation of the surgical wound with 300 ml of saline solution.
Trial: 10594201
Drug: Prophylactic systemic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic systemic antibiotics only (control group).
Trial: 9368804
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g added triglycerides
Trial: 9368804
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g added triglycerides
Trial: 9368804
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g added triglycerides
Trial: 9368804
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g added triglycerides
Trial: 9368804
Drug: All triglyceride
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All triglyceride amounts (0, 15, 30, 40 g)
Trial: 9368804
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g or more added triglycerides
Trial: 9368804
Drug: 0 to
RxNorm normalized name: U40 Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 to 40 g added triglycerides
Trial: 7692173
Drug: Isradipine regular
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine regular formulation (RF) 2.5 mg twice daily
Trial: 7692173
Drug: Isradipine modified
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine modified release (MR) 5 mg once daily
Trial: 3955199
Drug: Intravenous prenalterol
RxNorm normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prenalterol
Trial: 3955199
Drug: Sustained-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release formulation of prenalterol
Trial: 31724351
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy regimen combined with symptomatic treatment (antiemetic, acid-suppressive, liver-protecting drugs).
Trial: 28478653
Drug: Venlafaxine-lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine-lithium treatment strategy
Trial: 28478653
Drug: Imipramine-lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine-lithium treatment strategy
Trial: 25415373
Drug: Fixed fluence
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed fluence (FF) treatment
Trial: 25415373
Drug: Judged fluence
RxNorm normalized name: Florence fennel
DrugBank: Fennel (DB15615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Judged fluence (JF) treatment
Trial: 21654918
Drug: In-home training
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-home training for fathers, skills taught: following the child's lead, imitation with animation, commenting on the child, expectant waiting, duration: 12 weeks, frequency: twice a week
Trial: 17042843
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (30 mg x kg(‐1) before induction, 10 mg x kg(‐1) continuously intra‐operatively)
Trial: 12895688
Drug: Panax ginseng
RxNorm normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panax ginseng (200 mg G115)
Trial: 12895688
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (360 mg GK501)
Trial: 1281041
Drug: L-TAE +
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-TAE + ADR
Trial: 1281041
Drug: L-TAE
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-TAE
Trial: 30273343
Drug: Community-wide biannual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide biannual treatment with mass drug administration (MDA)
Trial: 30273343
Drug: Annual treatment
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual treatment of children alone with MDA
Trial: 27052303
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (maintaining daily routines)
Trial: 17878468
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of optimal bronchodilator therapy and/or supplemental oxygen therapy with exercise training
Trial: 16344836
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 30 mg
Trial: 16344836
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 20 mg
Trial: 16344836
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 40 mg
Trial: 16344836
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 60 mg
Trial: 12117301
Drug: Hyperhydration induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperhydration induced by ingestion of glycerol (1.1 g/kg body mass) and fluid (21.4 mL/kg body mass)
Trial: 11697710
Drug: Mean platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean platelet count before therapy